{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:52:19Z","timestamp":1793407939453,"version":"4.5.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      The TheraSphere Global Steering Committee reconvened to review clinical data and address knowledge gaps related to treatment and dosimetry in non-HCC indications using Yttrium-90 (\n                      <jats:sup>90<\/jats:sup>\n                      Y) glass microspheres.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A PubMed search was performed. References were reviewed and adjudicated by the Delphi method. Recommendations were graded according to the degree of recommendation and strength of consensus. Dosimetry focused on a mean dose approach, i.e., aiming for an average dose over either single or multicompartment volumes of interests. Committee discussion and consensus focused on optimal patient selection, disease presentation, liver function, tumour type, tumour vascularity, and curative\/palliative treatment intent for intrahepatic cholangiocarcinoma (iCCA) and colorectal and neuroendocrine carcinoma liver metastases (mCRC, mNET).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>For all indications, single compartment average perfused volume absorbed dose\u2009\u2265\u2009400\u00a0Gy is recommended for radiation segmentectomy and 150\u00a0Gy for radiation lobectomy. Single compartment 120\u00a0Gy for uni- and bilobar treatment reflects current clinical practice, which results in variable tumour and normal tissue absorbed doses. Therefore, multicompartment dosimetry is recommended for uni- and bilobar treatment, aiming for maximum 75\u00a0Gy to normal tissue and 150\u2013200\u00a0Gy (mCRC, mNET),\u2009\u2265\u2009205 (iCCA) tumour absorbed doses. These dose thresholds are preliminary and should be used with caution accounting for patient specific characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Consensus recommendations are provided to guide clinical and dosimetry approaches for\n                      <jats:sup>90<\/jats:sup>\n                      Y glass microsphere radioembolization in iCCA, mCRC and mNET.\n                    <\/jats:p>\n                    <jats:p>Clinical trial number: not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-025-07229-8","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T13:09:42Z","timestamp":1743340182000},"page":"3820-3832","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Clinical and dosimetric considerations for yttrium-90 glass microspheres radioembolization of intrahepatic cholangiocarcinoma, metastatic colorectal carcinoma, and metastatic neuroendocrine carcinoma: recommendations from an international multidisciplinary working group"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4902-9790","authenticated-orcid":false,"given":"Marnix","family":"Lam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riad","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beau","family":"Toskich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Cheenu","family":"Kappadath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Chiesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk","family":"Fowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Haste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Herman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth A.","family":"Padia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Sangro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Y.","family":"Sze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Garin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"7229_CR1","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jhep.2023.03.010","volume":"79","author":"European Association for the Study of the Liver","year":"2023","unstructured":"European Association for the Study of the Liver. EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma. J Hepatol. 2023;79:181\u2013208. https:\/\/doi.org\/10.1016\/j.jhep.2023.03.010.","journal-title":"J Hepatol"},{"key":"7229_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2023","unstructured":"Vogel A, Bridgewater J, Edeline J, Kelley RK, Kl\u00fcmpen HJ, Malka D, et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:127\u201340. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.506.","journal-title":"Ann Oncol"},{"key":"7229_CR3","doi-asserted-by":"publisher","first-page":"694","DOI":"10.6004\/jnccn.2023.0035","volume":"21","author":"AB Benson","year":"2023","unstructured":"Benson AB, D\u2019Angelica MI, Abrams T, Abbott DE, Ahmed A, Anaya DA, et al. NCCN guidelines(R) insights: biliary tract cancers, version 2.2023. J Natl Compr Canc Netw. 2023;21:694\u2013704. https:\/\/doi.org\/10.6004\/jnccn.2023.0035.","journal-title":"J Natl Compr Canc Netw"},{"key":"7229_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosello S, Arnold D, Normanno N, Taieb J, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:10\u201332. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.003.","journal-title":"Ann Oncol"},{"key":"7229_CR5","unstructured":"Benson AB, Venook AP, Al-Hawary MM, Chen YJ, Ciombor KK, Cohen S, et al. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 2 2023. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer Version 2 2023 - September 14, 2023: National Comprehensive Cancer Network; 2023."},{"key":"7229_CR6","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","volume":"31","author":"M Pavel","year":"2020","unstructured":"Pavel M, \u00d6berg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:844\u201360. https:\/\/doi.org\/10.1016\/j.annonc.2020.03.304.","journal-title":"Ann Oncol"},{"key":"7229_CR7","unstructured":"Bergsland E, Bart Rose J, Benson Iii AB, Berman Z, Blaszkowsky LS, Brock P, et al. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors (Version 1.2023). National Comprehensive Cancer Network; 2023."},{"key":"7229_CR8","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.jvir.2017.04.025","volume":"28","author":"RC Gaba","year":"2017","unstructured":"Gaba RC, Lokken RP, Hickey RM, Lipnik AJ, Lewandowski RJ, Salem R, et al. Quality improvement guidelines for transarterial chemoembolization and embolization of hepatic malignancy. J Vasc Interv Radiol. 2017;28:1210-23.e3. https:\/\/doi.org\/10.1016\/j.jvir.2017.04.025.","journal-title":"J Vasc Interv Radiol"},{"key":"7229_CR9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1053\/j.tvir.2019.02.008","volume":"22","author":"SA Padia","year":"2019","unstructured":"Padia SA. Y90 clinical data update: cholangiocarcinoma, neuroendocrine tumor, melanoma, and breast cancer metastatic disease. Tech Vasc Interv Radiol. 2019;22:81\u20136. https:\/\/doi.org\/10.1053\/j.tvir.2019.02.008.","journal-title":"Tech Vasc Interv Radiol"},{"key":"7229_CR10","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/jso.26223","volume":"123","author":"SA Padia","year":"2021","unstructured":"Padia SA, Johnson GE, Agopian VG, DiNorcia J, Srinivasa RN, Sayre J, et al. Yttrium-90 radiation segmentectomy for hepatic metastases: a multi-institutional study of safety and efficacy. J Surg Oncol. 2021;123:172\u20138. https:\/\/doi.org\/10.1002\/jso.26223.","journal-title":"J Surg Oncol"},{"key":"7229_CR11","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1007\/s00259-021-05642-3","volume":"49","author":"SC Ebbers","year":"2022","unstructured":"Ebbers SC, van Roekel C, Braat M, Barentsz MW, Lam M, Braat A. Dose-response relationship after yttrium-90-radioembolization with glass microspheres in patients with neuroendocrine tumor liver metastases. Eur J Nucl Med Mol Imaging. 2022;49:1700\u201310. https:\/\/doi.org\/10.1007\/s00259-021-05642-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7229_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/jamaoncol.2019.3702","volume":"6","author":"J Edeline","year":"2020","unstructured":"Edeline J, Touchefeu Y, Guiu B, Farge O, Tougeron D, Baumgaertner I, et al. Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2020;6:51\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2019.3702.","journal-title":"JAMA Oncol"},{"key":"7229_CR13","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1007\/s00259-021-05600-z","volume":"49","author":"M Weber","year":"2022","unstructured":"Weber M, Lam M, Chiesa C, Konijnenberg M, Cremonesi M, Flamen P, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2022;49:1682\u201399. https:\/\/doi.org\/10.1007\/s00259-021-05600-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7229_CR14","unstructured":"U.S. Food & Drug. PMA Summary of Safety and Effectiveness. https:\/\/www.fda.gov\/medical-devices\/recently-approved-devices\/theraspheretm-p200029; 2021."},{"key":"7229_CR15","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-022-05956-w","volume":"50","author":"R Salem","year":"2023","unstructured":"Salem R, Padia SA, Lam M, Chiesa C, Haste P, Sangro B, et al. Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging. 2023;50:328\u201343. https:\/\/doi.org\/10.1007\/s00259-022-05956-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7229_CR16","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3389\/fonc.2014.00210","volume":"4","author":"M Cremonesi","year":"2014","unstructured":"Cremonesi M, Chiesa C, Strigari L, Ferrari M, Botta F, Guerriero F, et al. Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective. Front Oncol. 2014;4:210. https:\/\/doi.org\/10.3389\/fonc.2014.00210.","journal-title":"Front Oncol"},{"key":"7229_CR17","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.2967\/jnumed.120.255745","volume":"62","author":"AA Alsultan","year":"2021","unstructured":"Alsultan AA, van Roekel C, Barentsz MW, Smits MLJ, Kunnen B, Koopman M, et al. Dose-response and dose-toxicity relationships for glass (90)Y radioembolization in patients with liver metastases from colorectal cancer. J Nucl Med. 2021;62:1616\u201323. https:\/\/doi.org\/10.2967\/jnumed.120.255745.","journal-title":"J Nucl Med"},{"key":"7229_CR18","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jvir.2022.12.017","volume":"34","author":"O Ahmed","year":"2023","unstructured":"Ahmed O, Yu Q, Patel M, Hwang G, Pillai A, Liao CY, et al. Yttrium-90 Radioembolization and concomitant systemic gemcitabine, cisplatin, and capecitabine as the first-line therapy for locally advanced intrahepatic cholangiocarcinoma. J Vasc Interv Radiol. 2023;34:702\u20139. https:\/\/doi.org\/10.1016\/j.jvir.2022.12.017.","journal-title":"J Vasc Interv Radiol"},{"key":"7229_CR19","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924\u20136. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD.","journal-title":"BMJ"},{"key":"7229_CR20","doi-asserted-by":"publisher","first-page":"311","DOI":"10.21037\/jgo.2017.11.02","volume":"9","author":"C Meiers","year":"2018","unstructured":"Meiers C, Taylor A, Geller B, Toskich B. Safety and initial efficacy of radiation segmentectomy for the treatment of hepatic metastases. J Gastrointest Oncol. 2018;9:311\u20135. https:\/\/doi.org\/10.21037\/jgo.2017.11.02.","journal-title":"J Gastrointest Oncol"},{"key":"7229_CR21","doi-asserted-by":"publisher","first-page":"3428","DOI":"10.1007\/s00261-021-02956-6","volume":"46","author":"I Kurilova","year":"2021","unstructured":"Kurilova I, Bendet A, Fung EK, Petre EN, Humm JL, Boas FE, et al. Radiation segmentectomy of hepatic metastases with Y-90 glass microspheres. Abdom Radiol. 2021;46:3428\u201336.","journal-title":"Abdom Radiol"},{"key":"7229_CR22","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jvir.2022.12.021","volume":"34","author":"AM Chiu","year":"2023","unstructured":"Chiu AM, Savoor R, Gordon AC, Riaz A, Sato KT, Hohlastos E, et al. Yttrium-90 radiation segmentectomy in oligometastatic secondary hepatic malignancies. J Vasc Interv Radiol. 2023;34:362\u20138. https:\/\/doi.org\/10.1016\/j.jvir.2022.12.021.","journal-title":"J Vasc Interv Radiol"},{"key":"7229_CR23","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1080\/02656736.2021.1933215","volume":"39","author":"P Entezari","year":"2022","unstructured":"Entezari P, Gabr A, Salem R, Lewandowski RJ. Yttrium-90 for colorectal liver metastasis - the promising role of radiation segmentectomy as an alternative local cure. Int J Hyperthermia. 2022;39:620\u20136. https:\/\/doi.org\/10.1080\/02656736.2021.1933215.","journal-title":"Int J Hyperthermia"},{"key":"7229_CR24","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/mnm.0000000000001813","volume":"45","author":"S Kesim","year":"2024","unstructured":"Kesim S, Balaban Genc ZC, Soydemir E, Baltacioglu F, Kissa TN, Ozdemir B, et al. Evaluating therapeutic efficacy of extended shelf-life 90 Y glass microspheres in transarterial radioembolization for colorectal cancer: a quantitative FDG PET\/CT analysis. Nucl Med Commun. 2024;45:268\u201377. https:\/\/doi.org\/10.1097\/mnm.0000000000001813.","journal-title":"Nucl Med Commun"},{"key":"7229_CR25","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/rlu.0000000000005565","volume":"50","author":"PM Dimopoulos","year":"2025","unstructured":"Dimopoulos PM, Sotirchos VS, Dunne-Jaffe C, Petre EN, Gonen M, Zhao K, et al. Voxel-based dosimetry predicts local tumor progression post 90Y radiation segmentectomy of colorectal liver metastases. Clin Nucl Med. 2025;50:133\u201342. https:\/\/doi.org\/10.1097\/rlu.0000000000005565.","journal-title":"Clin Nucl Med"},{"key":"7229_CR26","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jhep.2013.06.015","volume":"59","author":"M Vouche","year":"2013","unstructured":"Vouche M, Lewandowski RJ, Atassi R, Memon K, Gates VL, Ryu RK, et al. Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol. 2013;59:1029\u201336. https:\/\/doi.org\/10.1016\/j.jhep.2013.06.015.","journal-title":"J Hepatol"},{"key":"7229_CR27","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.2967\/jnumed.118.224394","volume":"60","author":"S van der Velden","year":"2019","unstructured":"van der Velden S, Braat M, Labeur TA, Scholten MV, van Delden OM, Bennink RJ, et al. A pilot study on hepatobiliary scintigraphy to monitor regional liver function in (90)Y radioembolization. J Nucl Med. 2019;60:1430\u20136. https:\/\/doi.org\/10.2967\/jnumed.118.224394.","journal-title":"J Nucl Med"},{"key":"7229_CR28","doi-asserted-by":"publisher","first-page":"E43","DOI":"10.21037\/jgo.2017.01.26","volume":"8","author":"JL Shah","year":"2017","unstructured":"Shah JL, Zendejas-Ruiz IR, Thornton LM, Geller BS, Grajo JR, Collinsworth A, et al. Neoadjuvant transarterial radiation lobectomy for colorectal hepatic metastases: a small cohort analysis on safety, efficacy, and radiopathologic correlation. J Gastrointest Oncol. 2017;8:E43-e51. https:\/\/doi.org\/10.21037\/jgo.2017.01.26.","journal-title":"J Gastrointest Oncol"},{"key":"7229_CR29","doi-asserted-by":"publisher","first-page":"751","DOI":"10.21037\/jgo-20-507","volume":"12","author":"A Ahmed","year":"2021","unstructured":"Ahmed A, Stauffer JA, LeGout JD, Burns J, Croome K, Paz-Fumagalli R, et al. The use of neoadjuvant lobar radioembolization prior to major hepatic resection for malignancy results in a low rate of post hepatectomy liver failure. J Gastrointest Oncol. 2021;12:751\u201361. https:\/\/doi.org\/10.21037\/jgo-20-507.","journal-title":"J Gastrointest Oncol"},{"key":"7229_CR30","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1007\/s00259-017-3707-3","volume":"44","author":"C Chiesa","year":"2017","unstructured":"Chiesa C, Sjogreen Gleisner K, Flux G, Gear J, Walrand S, Bacher K, et al. The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy. Eur J Nucl Med Mol Imaging. 2017;44:1783\u20136. https:\/\/doi.org\/10.1007\/s00259-017-3707-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7229_CR31","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.jvir.2016.12.1221","volume":"28","author":"P Haste","year":"2017","unstructured":"Haste P, Tann M, Persohn S, LaRoche T, Aaron V, Mauxion T, et al. Correlation of technetium-99m macroaggregated albumin and yttrium-90 glass microsphere biodistribution in hepatocellular carcinoma: a retrospective review of pretreatment single photon emission CT and posttreatment positron emission tomography\/CT. J Vasc Interv Radiol. 2017;28:722-30 e1. https:\/\/doi.org\/10.1016\/j.jvir.2016.12.1221.","journal-title":"J Vasc Interv Radiol"},{"key":"7229_CR32","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.2967\/jnumed.115.166942","volume":"57","author":"AF van den Hoven","year":"2016","unstructured":"van den Hoven AF, Rosenbaum CE, Elias SG, de Jong HW, Koopman M, Verkooijen HM, et al. Insights into the dose-response relationship of radioembolization with resin 90Y-microspheres: a prospective cohort study in patients with colorectal cancer liver metastases. J Nucl Med. 2016;57:1014\u20139. https:\/\/doi.org\/10.2967\/jnumed.115.166942.","journal-title":"J Nucl Med"},{"key":"7229_CR33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13550-019-0485-x","volume":"9","author":"E Jafargholi Rangraz","year":"2019","unstructured":"Jafargholi Rangraz E, Coudyzer W, Maleux G, Baete K, Deroose CM, Nuyts J. Multi-modal image analysis for semi-automatic segmentation of the total liver and liver arterial perfusion territories for radioembolization. EJNMMI Res. 2019;9:19. https:\/\/doi.org\/10.1186\/s13550-019-0485-x.","journal-title":"EJNMMI Res"},{"key":"7229_CR34","doi-asserted-by":"publisher","first-page":"879469","DOI":"10.1155\/2014\/879469","volume":"2014","author":"S Annunziata","year":"2014","unstructured":"Annunziata S, Treglia G, Caldarella C, Galiandro F. The role of 18F-FDG-PET and PET\/CT in patients with colorectal liver metastases undergoing selective internal radiation therapy with yttrium-90: a first evidence-based review. ScientificWorldJournal. 2014;2014:879469. https:\/\/doi.org\/10.1155\/2014\/879469.","journal-title":"ScientificWorldJournal"},{"key":"7229_CR35","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3390\/diagnostics12030715","volume":"12","author":"OD Bijlstra","year":"2022","unstructured":"Bijlstra OD, Boreel MME, van Mossel S, Burgmans MC, Kapiteijn EHW, Oprea-Lager DE, et al. The value of (18)F-FDG-PET-CT imaging in treatment evaluation of colorectal liver metastases: a systematic review. Diagnostics (Basel). 2022;12:715. https:\/\/doi.org\/10.3390\/diagnostics12030715.","journal-title":"Diagnostics (Basel)"},{"key":"7229_CR36","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1200\/JCO.21.01839","volume":"39","author":"MF Mulcahy","year":"2021","unstructured":"Mulcahy MF, Mahvash A, Pracht M, Montazeri AH, Bandula S, Martin RCG 2nd, et al. Radioembolization with chemotherapy for colorectal liver metastases: a randomized, open-label, international, multicenter, phase III trial. J Clin Oncol. 2021;39:3897\u2013907. https:\/\/doi.org\/10.1200\/JCO.21.01839.","journal-title":"J Clin Oncol"},{"key":"7229_CR37","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/oncolo\/oyae128","volume":"29","author":"R Salem","year":"2024","unstructured":"Salem R, Garin E, Boucher E, Fowers K, Lam M, Padia S, et al. Optimal patient selection for yttrium-90 glass plus chemotherapy in the treatment of colorectal liver metastases: additional quality of life, efficacy, and safety analyses from the EPOCH study. Oncologist. 2024;29:681\u20139. https:\/\/doi.org\/10.1093\/oncolo\/oyae128.","journal-title":"Oncologist"},{"issue":"Suppl 1","key":"7229_CR38","doi-asserted-by":"publisher","first-page":"S210","DOI":"10.1016\/j.acra.2021.03.033","volume":"28","author":"Z Haber","year":"2021","unstructured":"Haber Z, Lee EW, Price M, Wainberg Z, Hecht JR, Sayre J, et al. Survival advantage of Yttrium-90 radioembolization to systemic therapy in patients with hepatic metastases from colorectal cancer in the salvage setting: results of a matched pair study. Acad Radiol. 2021;28(Suppl 1):S210\u20137. https:\/\/doi.org\/10.1016\/j.acra.2021.03.033.","journal-title":"Acad Radiol"},{"key":"7229_CR39","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.ijrobp.2013.12.040","volume":"88","author":"R Hickey","year":"2014","unstructured":"Hickey R, Mulcahy MF, Lewandowski RJ, Gates VL, Vouche M, Habib A, et al. Chemoradiation of hepatic malignancies: prospective, phase 1 study of full-dose capecitabine with escalating doses of yttrium-90 radioembolization. Int J Radiat Oncol Biol Phys. 2014;88:1025\u201331. https:\/\/doi.org\/10.1016\/j.ijrobp.2013.12.040.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7229_CR40","doi-asserted-by":"publisher","first-page":"37912","DOI":"10.18632\/oncotarget.16007","volume":"8","author":"MS Dendy","year":"2017","unstructured":"Dendy MS, Ludwig JM, Kim HS. Predictors and prognosticators for survival with Yttrium-90 radioembolization therapy for unresectable colorectal cancer liver metastasis. Oncotarget. 2017;8:37912\u201322. https:\/\/doi.org\/10.18632\/oncotarget.16007.","journal-title":"Oncotarget"},{"key":"7229_CR41","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1007\/s00259-014-2799-2","volume":"41","author":"RJ Lewandowski","year":"2014","unstructured":"Lewandowski RJ, Memon K, Mulcahy MF, Hickey R, Marshall K, Williams M, et al. Twelve-year experience of radioembolization for colorectal hepatic metastases in 214 patients: survival by era and chemotherapy. Eur J Nucl Med Mol Imaging. 2014;41:1861\u20139. https:\/\/doi.org\/10.1007\/s00259-014-2799-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7229_CR42","doi-asserted-by":"publisher","first-page":"860","DOI":"10.21037\/jgo.2016.08.04","volume":"7","author":"N Fidelman","year":"2016","unstructured":"Fidelman N, Kerlan RK Jr, Hawkins RA, Pampaloni M, Taylor AG, Kohi MP, et al. Radioembolization with (90)Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study. J Gastrointest Oncol. 2016;7:860\u201374. https:\/\/doi.org\/10.21037\/jgo.2016.08.04.","journal-title":"J Gastrointest Oncol"},{"key":"7229_CR43","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1002\/hep.31819","volume":"74","author":"R Salem","year":"2021","unstructured":"Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, et al. Yttrium-90 radioembolization for the treatment of solitary unresectable HCC: the LEGACY study. Hepatology. 2021;74:2342\u201352. https:\/\/doi.org\/10.1002\/hep.31819.","journal-title":"Hepatology"},{"key":"7229_CR44","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/hep.27057","volume":"60","author":"M Vouche","year":"2014","unstructured":"Vouche M, Habib A, Ward TJ, Kim E, Kulik L, Ganger D, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology. 2014;60:192\u2013201. https:\/\/doi.org\/10.1002\/hep.27057.","journal-title":"Hepatology"},{"key":"7229_CR45","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1007\/s00259-020-04976-8","volume":"48","author":"A Gabr","year":"2021","unstructured":"Gabr A, Riaz A, Johnson GE, Kim E, Padia S, Lewandowski RJ, et al. Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants. Eur J Nucl Med Mol Imaging. 2021;48:580\u20133. https:\/\/doi.org\/10.1007\/s00259-020-04976-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7229_CR46","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1007\/s00259-022-05776-y","volume":"49","author":"SA Montazeri","year":"2022","unstructured":"Montazeri SA, De la Garza-Ramos C, Lewis AR, Lewis JT, LeGout JD, Sella DM, et al. Hepatocellular carcinoma radiation segmentectomy treatment intensification prior to liver transplantation increases rates of complete pathologic necrosis: an explant analysis of 75 tumors. Eur J Nucl Med Mol Imaging. 2022;49:3892\u20137. https:\/\/doi.org\/10.1007\/s00259-022-05776-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7229_CR47","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/s00259-017-3845-7","volume":"45","author":"X Palard","year":"2018","unstructured":"Palard X, Edeline J, Rolland Y, Le Sourd S, Pracht M, Laffont S, et al. Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2018;45:392\u2013401. https:\/\/doi.org\/10.1007\/s00259-017-3845-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7229_CR48","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2967\/jnumed.115.166082","volume":"57","author":"R Hickey","year":"2016","unstructured":"Hickey R, Lewandowski RJ, Prudhomme T, Ehrenwald E, Baigorri B, Critchfield J, et al. 90Y radioembolization of colorectal hepatic metastases using glass microspheres: safety and survival outcomes from a 531-patient multicenter study. J Nucl Med. 2016;57:665\u201371. https:\/\/doi.org\/10.2967\/jnumed.115.166082.","journal-title":"J Nucl Med"},{"key":"7229_CR49","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/j.jvir.2016.06.004","volume":"27","author":"JR Kallini","year":"2016","unstructured":"Kallini JR, Gabr A, Kulik L, Salem R, Lewandowski RJ. The utility of unilobar technetium-99m macroaggregated albumin to predict pulmonary toxicity in bilobar hepatocellular carcinoma prior to yttrium-90 radioembolization. J Vasc Interv Radiol. 2016;27:1453\u20136. https:\/\/doi.org\/10.1016\/j.jvir.2016.06.004.","journal-title":"J Vasc Interv Radiol"},{"key":"7229_CR50","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1016\/j.jvir.2017.05.011","volume":"28","author":"YK Su","year":"2017","unstructured":"Su YK, Mackey RV, Riaz A, Gates VL, Benson AB 3rd, Miller FH, et al. Long-term hepatotoxicity of yttrium-90 radioembolization as treatment of metastatic neuroendocrine tumor to the liver. J Vasc Interv Radiol. 2017;28:1520\u20136. https:\/\/doi.org\/10.1016\/j.jvir.2017.05.011.","journal-title":"J Vasc Interv Radiol"},{"key":"7229_CR51","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.ijrobp.2011.07.041","volume":"83","author":"K Memon","year":"2012","unstructured":"Memon K, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Sato KT, et al. Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. Int J Radiat Oncol Biol Phys. 2012;83:887\u201394. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.07.041.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7229_CR52","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1097\/SLA.0b013e3181728a45","volume":"247","author":"TK Rhee","year":"2008","unstructured":"Rhee TK, Lewandowski RJ, Liu DM, Mulcahy MF, Takahashi G, Hansen PD, et al. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg. 2008;247:1029\u201335. https:\/\/doi.org\/10.1097\/SLA.0b013e3181728a45.","journal-title":"Ann Surg"},{"issue":"1","key":"7229_CR53","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1477-2574.2011.00405.x","volume":"14","author":"M Shaheen","year":"2012","unstructured":"Shaheen M, Hassanain M, Aljiffry MM, Cabrera T, Chaudhury P, Simoneau \u00c8, et al. Predictors of response to radio-embolization (TheraSphere\u00ae) treatment of neuroendocrine liver metastasis. HPB (Oxford). 2012;14(1):60\u20136.","journal-title":"HPB (Oxford)"},{"key":"7229_CR54","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1111\/jgh.13752","volume":"32","author":"Z Jia","year":"2017","unstructured":"Jia Z, Paz-Fumagalli R, Frey G, Sella DM, McKinney JM, Wang W. Single-institution experience of radioembolization with yttrium-90 microspheres for unresectable metastatic neuroendocrine liver tumors. J Gastroenterol Hepatol. 2017;32:1617\u201323. https:\/\/doi.org\/10.1111\/jgh.13752.","journal-title":"J Gastroenterol Hepatol"},{"key":"7229_CR55","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00270-016-1478-z","volume":"40","author":"JX Chen","year":"2017","unstructured":"Chen JX, Rose S, White SB, El-Haddad G, Fidelman N, Yarmohammadi H, et al. Embolotherapy for neuroendocrine tumor liver metastases: prognostic factors for hepatic progression-free survival and overall survival. Cardiovasc Intervent Radiol. 2017;40:69\u201380. https:\/\/doi.org\/10.1007\/s00270-016-1478-z.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"7229_CR56","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.2967\/jnumed.124.267774","volume":"65","author":"M Watanabe","year":"2024","unstructured":"Watanabe M, Leyser S, Theysohn J, Schaarschmidt B, Ludwig J, Fendler WP, et al. Dose-response relationship in patients with liver metastases from neuroendocrine neoplasms undergoing radioembolization with (90)Y glass microspheres. J Nucl Med. 2024;65:1175\u201380. https:\/\/doi.org\/10.2967\/jnumed.124.267774.","journal-title":"J Nucl Med"},{"key":"7229_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2024.11.003","author":"AC Gordon","year":"2024","unstructured":"Gordon AC, Savoor R, Kircher SM, Kalyan A, Benson AB 3rd, Hohlastos E, et al. Ablative dose Y90 radiation segmentectomy for treatment of neuroendocrine liver metastases. J Vasc Interv Radiol. 2024. https:\/\/doi.org\/10.1016\/j.jvir.2024.11.003.","journal-title":"J Vasc Interv Radiol"},{"key":"7229_CR58","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.jamcollsurg.2019.12.026","volume":"230","author":"ME Egger","year":"2020","unstructured":"Egger ME, Armstrong E, Martin RC 2nd, Scoggins CR, Philips P, Shah M, et al. Transarterial chemoembolization vs radioembolization for neuroendocrine liver metastases: a multi-institutional analysis. J Am Coll Surg. 2020;230:363\u201370. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2019.12.026.","journal-title":"J Am Coll Surg"},{"key":"7229_CR59","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.jvir.2020.05.019","volume":"31","author":"BM Currie","year":"2020","unstructured":"Currie BM, Nadolski G, Mondschein J, Dagli M, Sudheendra D, Stavropoulos SW, et al. Chronic hepatotoxicity in patients with metastatic neuroendocrine tumor: transarterial chemoembolization versus transarterial radioembolization. J Vasc Interv Radiol. 2020;31:1627\u201335. https:\/\/doi.org\/10.1016\/j.jvir.2020.05.019.","journal-title":"J Vasc Interv Radiol"},{"key":"7229_CR60","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.2967\/jnumed.112.107482","volume":"53","author":"S Ezziddin","year":"2012","unstructured":"Ezziddin S, Meyer C, Kahancova S, Haslerud T, Willinek W, Wilhelm K, et al. 90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy. J Nucl Med. 2012;53:1663\u20139. https:\/\/doi.org\/10.2967\/jnumed.112.107482.","journal-title":"J Nucl Med"},{"key":"7229_CR61","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s00270-019-02350-2","volume":"43","author":"A Braat","year":"2020","unstructured":"Braat A, Ahmadzadehfar H, Kappadath SC, Stothers CL, Frilling A, Deroose CM, et al. Radioembolization with (90)Y resin microspheres of neuroendocrine liver metastases after initial peptide receptor radionuclide therapy. Cardiovasc Intervent Radiol. 2020;43:246\u201353. https:\/\/doi.org\/10.1007\/s00270-019-02350-2.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"7229_CR62","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2967\/jnumed.114.150565","volume":"56","author":"H Ilhan","year":"2015","unstructured":"Ilhan H, Goritschan AM, Paprottka P, Jakobs TF, Fendler WP, Bartenstein P, et al. Systematic evaluation of tumoral 99mTc-MAA uptake using SPECT and SPECT\/CT in 502 patients before 90Y radioembolization. J Nucl Med. 2015;56:333\u20138.","journal-title":"J Nucl Med"},{"key":"7229_CR63","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1053\/j.gastro.2011.04.054","volume":"141","author":"K Memon","year":"2011","unstructured":"Memon K, Kulik L, Lewandowski RJ, Wang E, Riaz A, Ryu RK, et al. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology. 2011;141:526\u201335. https:\/\/doi.org\/10.1053\/j.gastro.2011.04.054. (35.e1 2).","journal-title":"Gastroenterology"},{"key":"7229_CR64","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1007\/s00261-018-1505-4","volume":"43","author":"EA Aherne","year":"2018","unstructured":"Aherne EA, Pak LM, Goldman DA, Gonen M, Jarnagin WR, Simpson AL, et al. Intrahepatic cholangiocarcinoma: can imaging phenotypes predict survival and tumor genetics? Abdom Radiol (NY). 2018;43:2665\u201372. https:\/\/doi.org\/10.1007\/s00261-018-1505-4.","journal-title":"Abdom Radiol (NY)"},{"key":"7229_CR65","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.18632\/oncotarget.28060","volume":"12","author":"R Paz-Fumagalli","year":"2021","unstructured":"Paz-Fumagalli R, Core J, Padula C, Montazeri S, McKinney J, Frey G, et al. Safety and initial efficacy of ablative radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma. Oncotarget. 2021;12:2075\u201388. https:\/\/doi.org\/10.18632\/oncotarget.28060.","journal-title":"Oncotarget"},{"key":"7229_CR66","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1245\/s10434-009-0454-0","volume":"16","author":"RC Gaba","year":"2009","unstructured":"Gaba RC, Lewandowski RJ, Kulik LM, Riaz A, Ibrahim SM, Mulcahy MF, et al. Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol. 2009;16:1587\u201396. https:\/\/doi.org\/10.1245\/s10434-009-0454-0.","journal-title":"Ann Surg Oncol"},{"key":"7229_CR67","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/jso.24269","volume":"114","author":"RJ Lewandowski","year":"2016","unstructured":"Lewandowski RJ, Donahue L, Chokechanachaisakul A, Kulik L, Mouli S, Caicedo J, et al. (90) Y radiation lobectomy: Outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes. J Surg Oncol. 2016;114:99\u2013105. https:\/\/doi.org\/10.1002\/jso.24269.","journal-title":"J Surg Oncol"},{"key":"7229_CR68","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s00270-022-03250-8","volume":"45","author":"M Arora","year":"2022","unstructured":"Arora M, Toskich BB, Lewis AR, Padula CA, Montazeri SA, Ritchie C, et al. Radiation segmentectomy for the treatment of primary hepatic malignancies of the caudate lobe: a case series. Cardiovasc Intervent Radiol. 2022;45:1485\u201393. https:\/\/doi.org\/10.1007\/s00270-022-03250-8.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"7229_CR69","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.jceh.2022.03.008","volume":"12","author":"P Kumar","year":"2022","unstructured":"Kumar P, Mhaskar R, Kim R, Anaya D, Frakes J, Hoffe S, et al. Unresectable intrahepatic cholangiocarcinoma treated with radiation segmentectomy\/lobectomy using yttrium 90-labeled glass microspheres. J Clin Exp Hepatol. 2022;12:1259\u201363. https:\/\/doi.org\/10.1016\/j.jceh.2022.03.008.","journal-title":"J Clin Exp Hepatol"},{"key":"7229_CR70","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1016\/j.jvir.2023.07.028","volume":"34","author":"Q Yu","year":"2023","unstructured":"Yu Q, Patel M, Kwak D, Ungchusri E, Wang Y, Van Ha T, et al. Segmental yttrium-90 radioembolization using glass microspheres greater than 400 gray for the treatment of intrahepatic cholangiocarcinoma: a preliminary experience. J Vasc Interv Radiol. 2023;34:1970-6.e1. https:\/\/doi.org\/10.1016\/j.jvir.2023.07.028.","journal-title":"J Vasc Interv Radiol"},{"key":"7229_CR71","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1007\/s00330-023-10203-3","volume":"34","author":"Q Yu","year":"2024","unstructured":"Yu Q, Ungchusri E, Pillai A, Liao C-Y, Baker T, Fung J, et al. Selective internal radiation therapy using yttrium-90 microspheres for treatment of localized and locally advanced intrahepatic cholangiocarcinoma. Eur Radiol. 2024;34:2374\u201383. https:\/\/doi.org\/10.1007\/s00330-023-10203-3.","journal-title":"Eur Radiol"},{"key":"7229_CR72","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1007\/s00259-018-3990-7","volume":"45","author":"V Manceau","year":"2018","unstructured":"Manceau V, Palard X, Rolland Y, Pracht M, Le Sourd S, Laffont S, et al. A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and 90Y-loaded glass microsphere selective internal radiation therapy. Eur J Nucl Med Mol Imaging. 2018;45:1731\u201341. https:\/\/doi.org\/10.1007\/s00259-018-3990-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7229_CR73","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.21037\/jgo-23-210","volume":"14","author":"S Young","year":"2023","unstructured":"Young S, Torkian P, Flanagan S, D\u2019Souza D, Sanghvi T, Golzarian J. Intrahepatic cholangiocarcinoma: a dose threshold evaluation in those undergoing transarterial radioembolization. J Gastrointest Oncol. 2023;14:2202\u201311. https:\/\/doi.org\/10.21037\/jgo-23-210.","journal-title":"J Gastrointest Oncol"},{"key":"7229_CR74","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1097\/rlu.0000000000000904","volume":"40","author":"J Edeline","year":"2015","unstructured":"Edeline J, Du FL, Rayar M, Rolland Y, Beuzit L, Boudjema K, et al. Glass microspheres 90Y selective internal radiation therapy and chemotherapy as first-line treatment of intrahepatic cholangiocarcinoma. Clin Nucl Med. 2015;40:851\u20135. https:\/\/doi.org\/10.1097\/rlu.0000000000000904.","journal-title":"Clin Nucl Med"},{"key":"7229_CR75","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.jvir.2018.04.001","volume":"29","author":"A Gangi","year":"2018","unstructured":"Gangi A, Shah J, Hatfield N, Smith J, Sweeney J, Choi J, et al. Intrahepatic cholangiocarcinoma treated with transarterial yttrium-90 glass microsphere radioembolization: results of a single institution retrospective study. J Vasc Interv Radiol. 2018;29:1101\u20138. https:\/\/doi.org\/10.1016\/j.jvir.2018.04.001.","journal-title":"J Vasc Interv Radiol"},{"key":"7229_CR76","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00259-018-4199-5","volume":"46","author":"H Bourien","year":"2019","unstructured":"Bourien H, Palard X, Rolland Y, Le Du F, Beuzit L, Uguen T, et al. Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-center experience. Eur J Nucl Med Mol Imaging. 2019;46:669\u201376. https:\/\/doi.org\/10.1007\/s00259-018-4199-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7229_CR77","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1007\/s00270-021-02834-0","volume":"44","author":"B Cheng","year":"2021","unstructured":"Cheng B, Villalobos A, Sethi I, Wagstaff W, Galt J, Brandon D, et al. Determination of tumor dose response thresholds in patients with chemorefractory intrahepatic cholangiocarcinoma treated with resin and glass-based Y90 radioembolization. Cardiovasc Intervent Radiol. 2021;44:1194\u2013203. https:\/\/doi.org\/10.1007\/s00270-021-02834-0.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"7229_CR78","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1245\/s10434-014-4365-3","volume":"22","author":"M Rayar","year":"2015","unstructured":"Rayar M, Sulpice L, Edeline J, Garin E, Levi Sandri GB, Meunier B, et al. Intra-arterial yttrium-90 radioembolization combined with systemic chemotherapy is a promising method for downstaging unresectable huge intrahepatic cholangiocarcinoma to surgical treatment. Ann Surg Oncol. 2015;22:3102\u20138. https:\/\/doi.org\/10.1245\/s10434-014-4365-3.","journal-title":"Ann Surg Oncol"},{"key":"7229_CR79","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.jvir.2022.02.016","volume":"33","author":"DA Schartz","year":"2022","unstructured":"Schartz DA, Porter M, Schartz E, Kallas J, Gupta A, Butani D, et al. Transarterial yttrium-90 radioembolization for unresectable intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Vasc Interv Radiol. 2022;33:679\u201386. https:\/\/doi.org\/10.1016\/j.jvir.2022.02.016.","journal-title":"J Vasc Interv Radiol"},{"key":"7229_CR80","doi-asserted-by":"publisher","first-page":"4530","DOI":"10.3390\/curroncol28060384","volume":"28","author":"C Goislard de Monsabert","year":"2021","unstructured":"Goislard de Monsabert C, Touchefeu Y, Guiu B, Campillo-Gimenez B, Farges O, Tougeron D, et al. Selective internal radiation combined with chemotherapy maintains the quality of life in intrahepatic cholangiocarcinomas. Curr Oncol. 2021;28:4530\u201341. https:\/\/doi.org\/10.3390\/curroncol28060384.","journal-title":"Curr Oncol"},{"key":"7229_CR81","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.nucmedbio.2018.01.001","volume":"59","author":"N Nezami","year":"2018","unstructured":"Nezami N, Kokabi N, Camacho JC, Schuster DM, Xing M, Kim HS. (90)Y radioembolization dosimetry using a simple semi-quantitative method in intrahepatic cholangiocarcinoma: Glass versus resin microspheres. Nucl Med Biol. 2018;59:22\u20138. https:\/\/doi.org\/10.1016\/j.nucmedbio.2018.01.001.","journal-title":"Nucl Med Biol"},{"key":"7229_CR82","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.1007\/s00330-021-08501-9","volume":"32","author":"S Young","year":"2022","unstructured":"Young S, Chen T, Flanagan S, Golzarian J, Sanghvi T. Realized tumor to normal ratios in hepatocellular carcinoma patients undergoing transarterial radioembolization: a retrospective evaluation. Eur Radiol. 2022;32:4160\u20137. https:\/\/doi.org\/10.1007\/s00330-021-08501-9.","journal-title":"Eur Radiol"},{"key":"7229_CR83","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.jvir.2023.05.026","volume":"34","author":"B Kis","year":"2023","unstructured":"Kis B, Shridhar R, Mhaskar R, Gyano M, Frakes JM, El-Haddad G, et al. Radioembolization with yttrium-90 glass microspheres as a first-line treatment for unresectable intrahepatic cholangiocarcinoma-a prospective feasibility study. J Vasc Interv Radiol. 2023;34:1547\u201355. https:\/\/doi.org\/10.1016\/j.jvir.2023.05.026.","journal-title":"J Vasc Interv Radiol"},{"key":"7229_CR84","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.jvir.2019.03.018","volume":"30","author":"J White","year":"2019","unstructured":"White J, Carolan-Rees G, Dale M, Patrick HE, See TC, Bell JK, et al. Yttrium-90 transarterial radioembolization for chemotherapy-refractory intrahepatic cholangiocarcinoma: a prospective. Observational Study J Vasc Interv Radiol. 2019;30:1185\u201392. https:\/\/doi.org\/10.1016\/j.jvir.2019.03.018.","journal-title":"Observational Study J Vasc Interv Radiol"},{"key":"7229_CR85","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.jvir.2013.02.031","volume":"24","author":"S Mouli","year":"2013","unstructured":"Mouli S, Memon K, Baker T, Benson AB 3rd, Mulcahy MF, Gupta R, et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol. 2013;24:1227\u201334. https:\/\/doi.org\/10.1016\/j.jvir.2013.02.031.","journal-title":"J Vasc Interv Radiol"},{"key":"7229_CR86","doi-asserted-by":"publisher","first-page":"931","DOI":"10.3390\/diagnostics11060931","volume":"11","author":"C Allimant","year":"2021","unstructured":"Allimant C, Deshayes E, Kafrouni M, Santoro L, de Verbizier D, Fourcade M, et al. Hepatobiliary scintigraphy and glass (90)Y radioembolization with personalized dosimetry: dynamic changes in treated and nontreated liver. Diagnostics (Basel). 2021;11:931. https:\/\/doi.org\/10.3390\/diagnostics11060931.","journal-title":"Diagnostics (Basel)"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07229-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07229-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07229-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T08:26:36Z","timestamp":1757147196000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07229-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":86,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["7229"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07229-8","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"assertion":[{"value":"13 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"All authors are advisors to Boston Scientific Corporation. Marnix Lam is an advisor to Terumo, Novartis, Oncosil, BD, and Quirem, and receives research support from Boston Scientific, Terumo, Quirem, and Novartis. Riad Salem is a consultant for AstraZeneca, Genentech, Sirtex, Cook, Eisai, Bard, and QED Therapeutics. Beau Toskich is a consultant for AstraZeneca, Genentech, Eisai, Sirtex, Turnstone Biologics, Johnson and Johnson, HistoSonics, and Vivos. S. Cheenu Kappadath is a consultant for Sirtex, ABK Biomedical, and Terumo. Carlo Chiesa is a consultant for Terumo, and he received a research grant in 2017 from Boston Scientific. Kirk Fowers is a non-commercial employee of Boston Scientific Corporation. Joseph M. Herman is a employee of HistoSonics, and received institutional support for the Canopy Cancer Collective Learning Health Network. Edward Kim is an advisory board member and speaker for Boston Scientific, a consultant for Bristol-Myers Squibb, and an advisory board member for Genentech and Eisai. Thomas Leung is a consultant for Sirtex, AstraZeneca, Eisai, and Ipsen. Siddharth Padia is a consultant for Teleflex Medical, Guerbet, Varian Medical Systems, and Johnson and Johnson. Bruno Sangro received consulting fees from Adaptimmune, AstraZeneca, Bayer, BMS, Eisai, Exelixis, Eli Lilly, Ipsen, Merch, Onxeo, Roche, Sirtex, and Terumo; lecture fees from AstraZeneca, Bayer, BMS, Eisai, Eli Lilly, Incyte, Ipsen, Roche, and Sirtex; and institutional grants from BMS and Sirtex. Daniel Y. Sze serves on Independent Data Safety Monitoring Boards for W.L. Gore, FluidX, and Replimune, and is the Editor in Chief of the Journal of Vascular and Interventional Radiology.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}